

## Clinical trial using BioAtla's Conditionally Active Biologics for cancer treatment

09 January 2018 | News

Active Biologics (CAB) platform exploits the unique microenvironment of diseased tissue to more effectively target cancer.



BioAtla, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics.

The company announced that Shanghai Sinobioway Sunterra Biotechnology, a partner of F1 Oncology, Inc. has received ethics committee approval of a clinical trial for two novel, conditionally active chimeric antigen receptor T cell (CAB-CAR-T) product candidates targeting Axl and Ror2 for the treatment of metastatic renal cell carcinoma.

The precision medicine-driven clinical trial will enroll patients in China with multi-organ, recurrent/refractory metastatic renal cell carcinoma based on expression of the Axl or Ror2 targets in tumor biopsy.

F1 Oncology, BioAtla's partner in CAB technology applications for adoptive cellular therapies (ACTs), combines BioAtla's CAB technology with F1 Oncology's proprietary technologies with the goal of developing and commercializing CAB-CAR-T therapies for the treatment of solid tumor malignancies.

CAB-CAR-T cell therapies are designed to be conditionally active only in the tumor microenvironment and therefore help reduce potential adverse events associated with on-target, off-tumor effects of CAR-T therapies.

In 2016 BioAtla granted F1 Oncology an exclusive worldwide license under patents and know-how controlled by BioAtla to discover, develop, manufacture and commercialize ACT preparations and treatments for cancer.